Related resources
Search for item elsewhere
University researcher(s)
Academic department(s)
Urinary eosinophilic protein X, atopy, and symptoms suggestive of allergic disease at 3 years of age.
Gore C, Peterson C, Kissen P, Simpson B, Lowe L, Woodcock AA, Custovic A
J Allergy Clin Immunol. 2003;112( 4):702-8.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
BACKGROUND: Urinary eosinophilic protein X (U-EPX) measurement is easy to perform in children.However, its use for prediction, diagnosis, and monitoring of asthma andatopy is unclear. OBJECTIVE: We sought to investigate the relationshipbetween U-EPX and clinical phenotypes suggestive of allergic diseases.METHODS: U-EPX measurement (RIA), respiratory questionnaires, and skintesting were completed at age 3 years in 903 children followedprospectively from birth. Specific airway resistance was measured in 503currently asymptomatic children by using whole-body plethysmography duringtidal breathing. RESULTS: Nonatopic children with wheezing or eczema hadslightly increased U-EPX levels compared with nonatopic asymptomaticchildren. U-EPX levels (geometric mean EPX/creatinine ratio) were asfollows: nonatopic asymptomatic children (n = 313), 61.3 microg/mmol (95%CI, 56.4-66.6 microg/mmol); nonatopic children with wheezing (n = 148),71.2 microg/mmol (95% CI, 63.2-80.1 microg/mmol); nonatopic children witheczema (n = 90), 65.7 microg/mmol (95% CI, 56.7-76.2 microg/mmol); andnonatopic children with wheezing and eczema (n= 86), 79.7 microg/mmol (95%CI, 67.4-94.3 microg/mmol). Children who had persistent atopy early inlife had significantly higher U-EPX levels at age 3 years (nonatopic at 1and 3 years [n = 263], 63.4 microg/mmol [95% CI, 58.4-69.0 microg/mmol];atopic at 1 but not 3 years [n = 24], 65.1 microg/mmol [95% CI, 43.8-96.7microg/mmol]; nonatopic at 1 year and atopic at 3 years [n = 62], 90.0microg/mmol [95% CI, 74.6-108.4 microg/mmol]; atopic at 1 and 3 years [n =35], 111.5 microg/mmol [95% CI, 89.2-139.3 microg/mmol]; P <.002).Atopy alone and with wheezing, eczema, or both was associated withsignificantly increased U-EPX levels (P <.0001). Wheezing appeared tobe associated with higher U-EPX levels compared with eczema in both atopicand nonatopic children. The highest U-EPX level was found in atopicchildren with a history of wheezing and eczema (P <.0001). There was norelationship between U-EPX level and lung function. CONCLUSION: U-EPXlevel reflects the presence of atopy and associated symptoms and might beuseful for monitoring the progression of allergic disease.
Keyword(s)
Animals; Animals, Domestic; Child, Preschool; Environmental Exposure; Eosinophil-Derived Neurotoxin; Humans; Medical Records; Multivariate Analysis; Prospective Studies; Skin Tests; complications: Hypersensitivity; etiology: Cough; etiology: Dermatitis, Atopic; etiology: Eczema; etiology: Respiratory Sounds; physiopathology: Lung; urine: Ribonucleases